Posts tagged:

News

Company Announcement

ImmVirX enters the clinic with next generation oncolytic virus

Company Announcements

April 6, 2023

ImmVirX enters the clinic with next generation oncolytic virus

Company Announcements

May 19, 2021

by

Dr Malcolm McColl

AFR Higher Education Award Research Commercialisation

AFR Higher Education Award Research Commercialisation

Nov 13, 2020

by

ImmVirX reports on operations for FY22

Company Announcements

ImmVirX reports on operations for FY22

Company Announcements

May 19, 2021

by

ImmVirX closes upsized $25m Series A financing

Company Announcements

ImmVirX closes upsized $25m Series A financing

Company Announcements

May 19, 2021

by

Resignation of Chairman – Peter Turvey

Company Announcements

Resignation of Chairman – Peter Turvey

Company Announcements

May 19, 2021

by

Bioshares Interview: Malcolm McColl, CEO ImmVirX

Bioshares Interview: Malcolm McColl, CEO ImmVirX

Nov 13, 2020

by

ImmVirX Announces $22 Million Series A Financing

Company Announcements

ImmVirX Announces $22 Million Series A Financing

Company Announcements

May 19, 2021

by

Viralytics band gets back together for ImmVirX cancer start-up

Viralytics band gets back together for ImmVirX cancer start-up

Nov 13, 2020

by

$500m Cancer team reassembled

$500m Cancer team reassembled

Nov 13, 2020

by

New biotech venture going viral in battle against cancer

New biotech venture going viral in battle against cancer

Nov 13, 2020

by

ImmVirX featured in a recent ABC coverage of the Australian Biotech sector

ImmVirX featured in a recent ABC coverage of the Australian Biotech sector

Nov 13, 2020

by

The Newcastle Herald features Immvirx on its work to develop cutting-edge cancer therapies

The Newcastle Herald features Immvirx on its work to develop cutting-edge cancer therapies

Nov 13, 2020

by

Join Our Mailing List

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Our mission is to improve outcomes for patients with cancers in which immunotherapy treatments have limited effect